153
Participants
Start Date
October 10, 2018
Primary Completion Date
May 29, 2024
Study Completion Date
May 29, 2024
CT1812
Active Study Drug
Placebo
Non-active study drug
Alfred Health, Melbourne
Melbourne Health, Parkville
St Vincent's Hospital Sydney, Ivanhoe
Fundación Neuropolis - Hospital Viamed Montecanal, Zaragoza
Australian Alzheimer's Research Foundation, Nedlands
INEP, Prague
Alzheimer's Memory Center, Charlotte
A-Shine S.R.O, Pilsen
Hospital Clinico Universitario Virgen De La Arrixaca, El Palmar
Charter Research, Lady Lake
Compass Research LLC- Bioclinica Research, The Villages
ClinCloud, LLC, Maitland
ClinCloud, Viera
Allied Biomedical Research Institute, Miami
JEM Research Institute, Atlantis
Centro de Salud San Juan, Salamanca
Hospital Victoria EUGENIA. Unidad de Neurociencias., Seville
Neuro Behavirol Clinical Research C, North Canton
Vestra Clinics, Rychnov nad Kněžnou
21st Century Neurology/ Xenoscience Inc., Phoenix
Imaging Endpoints, Scottsdale
Ki Health Partners, LLC dba New England Institute for Clinical Research, Stamford
The Ohio State University - Wexner, Columbus
Neuro Health Centrum ltd, Brno
NeuropsychiatrieHK S.R.O, Hradec Králové
Clintrial S.R.O, Prague
Neuropsychiatrie s.r.o., Prague
Forbeli S.R.O, Prague
Brain Research Den Bosch, 's-Hertogenbosch
Brain Research Center Amsterdam, Amsterdam
Brain Research Center Zwolle, Zwolle
Fundación ACE, Barcelona
Lead Sponsor
National Institute on Aging (NIA)
NIH
Cognition Therapeutics
INDUSTRY